**Supplementary Table 1.** Baseline characteristics by QRS q­uartiles

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Characteristic** | **Total Population** | **QRS** **quartiles (ms)** | | | | **P-trend** |
| **N=2,759** | **Q1 (<88)**  **N=872** | **Q2 (88-92)**  **N=614** | **Q3 (94-102)**  **N=768** | **Q4 (>103)**  **N=505** |
| Age (years) | 58 ± 11 | 57 ± 12 | 57 ± 12 | 58 ± 11 | 60 ± 10 | <0.001 |
| Male | 1,505 (55%) | 310 (36%) | 339 (55%) | 484 (63%) | 372 (74%) | <0.001 |
| Race/ethnicity |  |  |  |  |  | <0.01 |
| White | 1,281 (46%) | 366 (42%) | 289 (47%) | 392 (51%) | 234 (46%) |  |
| Black | 1,206 (44%) | 405 (46%) | 265 (43%) | 306 (40%) | 230 (46%) |  |
| Other | 272 (10%) | 101 (12%) | 60 (10%) | 70 (9%) | 41 (8%) |  |
| Body mass index (kg/m2) | 31.9 ± 7.8 | 31.2 ± 8.5 | 31.7 ± 8.0 | 31.8 ± 7.0 | 33.2 ± 7.4 | <0.001 |
| Diabetes | 1,256 (46%) | 382 (44%) | 267 (44%) | 357 (47%) | 250 (50%) | 0.03 |
| Systolic blood pressure | 128 ± 22 | 125 ± 21 | 128 ± 23 | 128 ± 22 | 130 ± 22 | <0.001 |
| Coronary artery disease | 511 (19%) | 112 (13%) | 108 (18%) | 152 (20%) | 139 (28%) | <0.001 |
| Heart failure | 170 (6%) | 45 (5%) | 30 (5%) | 33 (4%) | 62 (12%) | <0.001 |
| Stroke | 247 (9%) | 74 (9%) | 44 (7%) | 68 (9%) | 61 (12%) | 0.04 |
| eGFR (CKD-EPI, ml/min/1.73 m²) | 45 ± 15 | 46 ± 15 | 46 ± 15 | 45 ± 15 | 44 ± 15 | <0.01 |
| 24-hour urine protein (g/24h) | 0.17  [0.07-0.82] | 0.13  [0.06-0.63] | 0.18  [0.07-0.96] | 0.22  [0.08-0.98] | 0.21  [0.08-0.77] | <0.001 |
| Hematocrit (%) | 37.9 ± 5.0 | 37.5 ± 4.9 | 38.1 ± 5.1 | 38.2 ± 5.0 | 38.1 ± 4.8 | <0.01 |
| Serum albumin (g/dL) | 3.96 ± 0.46 | 3.97 ± 0.48 | 3.96 ± 0.47 | 3.98 ± 0.45 | 3.94 ± 0.42 | 0.56 |
| Serum potassium (mEq/L) | 4.35 ± 0.53 | 4.39 ± 0.53 | 4.35 ± 0.52 | 4.34 ± 0.53 | 4.28 ± 0.54 | <0.001 |
| Serum calcium (mg/dL) | 9.20 ± 0.50 | 9.24 ± 0.52 | 9.19 ± 0.47 | 9.19 ± 0.49 | 9.16 ± 0.52 | <0.01 |
| ACEI or ARB use | 1,867 (68%) | 550 (64%) | 408 (67%) | 551 (72%) | 358 (72%) | <0.001 |
| Beta blocker use | 1260 (46%) | 359 (42%) | 265 (44%) | 366 (48%) | 270 (54%) | <0.001 |
| Calcium channel blocker use | 1,095 (40%) | 284 (33%) | 231 (38%) | 338 (44%) | 242 (48%) | <0.001 |
| Potassium sparing diuretic use | 261 (10%) | 84 (10%) | 63 (10%) | 54 (7%) | 60 (12%) | 0.80 |
| Loop diuretic use | 943 (34%) | 252 (29%) | 199 (33%) | 272 (36%) | 220 (44%) | <0.001 |
| Thiazide diuretic use | 790 (29%) | 259 (30%) | 174 (29%) | 209 (27%) | 148 (30%) | 0.61 |
| Statin use | 1,483 (54%) | 434 (50%) | 328 (54%) | 426 (56%) | 295 (59%) | <0.001 |
| Warfarin use | 71 (2.6%) | 18 (2.1%) | 9 (1.5%) | 24 (3.1%) | 20 (4.0%) | 0.01 |

Note: Continuous variables presented as mean ± standard deviation if normally distributed or median (25th-75th percentile) if non-normally distributed; categorical variables presented as count (%).

Baseline characteristics, according to quartiles of QRS, were compared with tests for trend based on linear regression, chi-square trend test, and the Cuzick nonparametric trend test.

Abbreviations. eGFR: estimated glomerular filtration rate, CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration, ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker.